Introduction
Cancer is one of the leading causes of premature morbidity and mortality. Based on current projections, cancer deaths will continue to rise, with nine million people estimated to die from the disease in 2015, and more than 11 million in 2030. Because cancer disproportionately affects the elderly, the resulting economic burden will become an even greater concern in future as a result of the ageing "baby boomer" population. There has been a significant advancement in the understanding of the mechanisms of carcinogenesis in recent years. However, the improvement in treatment modalities for cancer is lagging behind this advancement [1] . This is due to the fact that the cancer has a complex behaviour with each tumor type consisting of a large number of subtypes. Each subtype has a distinct clinical behaviour and there is a different response to each during the treatment.
The management of various cancers and their cures can become very difficult if the disease is not detected at an early stage. Early detection, on the other hand, is difficult due to the lack of specific biomarkers for diagnosis of the disease at early stages. Over the last decade, major efforts have been aimed at biomarker discovery and their clinical importance, especially after the completion of the Human Genome Project that led to advances in proteomic technologies. The discovery of cancer biomarkers is top priority in this field due to their anticipated critical role in early diagnosis, therapy guidance, and prognosis monitoring of different cancer types. Lung cancer is usually not detected until it has progressed to an advanced stage because the early-stage disease does not typically cause symptoms. Almost 99% of the tumors in lungs are malignant [2] . Lung cancer has become one of the world's leading causes of preventable deaths, though some decline in rate of its incidence was observed from [2004] [2005] [2006] [2007] [2008] [3, 4] . It has been estimated that 160,340 lung cancer deaths, accounting for about 28% of all cancer deaths, occurred in 2012 [5] . The link between cigarette smoking and lung cancer was established as early as the 1950s through epidemiologic studies [6] . Laboratory evidence has also demonstrated a strong etiological association of lung cancer with tobacco smoke containing high levels of volatile N-nitrosamines, such as N-nitrosodimethylamine, N-nitrosopyrrolidine, N-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) [7] . These nitrosamines pose a high risk of causing cancers of the lung, larynx, oral cavity, oesophagus, pancreas and bladder, while tobacco chewing is primarily associated with increased incidences of oral cavity and oesophageal cancers [8] . An etiological role of NNK in induction of human lung cancer is supported by evidence showing that NNK is activated by multiple forms of cytochrome P-450 isoenzymes to form DNA-damaging adducts in human lung tissue [9] . NNK is shown to induce lung adenocarcinoma in mice, rats and Syrian golden hamsters independent of its route of administration [10] [11] [12] . Other factors that may lead to lung cancer include air pollution from factories and motor vehicles, asbestos and radon exposure, poor diet, low socioeconomic status, and genetic inheritance.
Histopathological classification of lung cancer
The diagnosis of lung cancer still depends primarily on imaging techniques such as x-ray and computed tomography scans, or biopsy of the suspicious mass together with histopathological examination to confirm the diagnosis. The heterogeneity of lung tumors adds further difficulty in its early diagnosis. The vast majority of lung cancers are carcinomas, arising from the epithelial cells. On the basis of the size and appearance, lung tumors have been histologically classified by WHO into two main types: non-small cell lung carcinoma (NSCLC) accounting for around 75% of the total lung cancer types, and small cell lung carcinoma (SCLC) accounting for the remaining 25% (Table 1 ) [13] . Histological sub-types of NSCLC include squamous cell carcinoma (25%), adenocarcinoma (40%), large cell carcinoma (10%); SCLC types include small cell carcinoma and combined small cell carcinoma, and there are also many additional subtypes of decreasing frequency [14] . Some types of lung tumors outside these two categories are significantly less common and often have not been studied extensively. These include: adenosquamous carcinoma, carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements, carcinoid tumor, carcinomas of salivary gland type and unclassified carcinoma. This classification based on histological criteria has important implications for clinical management and prognosis of the disease. The survival rate for patients with lung cancer is poor, only 15% of patients survive for 5 years after diagnosis [4] . Detection of lung cancers at stage I can increase the 5-year survival rate to 80%, compared with the current rate of 15% in NSCLC and just 5% in SCLC patients [15, 16] . Development of new biomarkers that are lung cancer-specific and capable of early detection are essential tools in clinical management of this disease.
Proteomics in biomarker discovery
Proteomics is the study of large-scale protein expression patterns that moves beyond simple identification of a protein for the study of its isoforms, modifications Table 1 . Histopathological classification of lung cancer [13] . and interactions [17] . During the last 10 years, both genomic as well as proteomic approaches have been used for biomarker studies. While cancer development is driven by both epigenetic and genetic alterations, genomic studies hold great potential for deciphering molecular mechanisms that lead to the malignancy [18] . Proteomics can help provide invaluable new targets for therapeutic intervention [19] . Proteins are the potential candidate targets for diagnosis and therapy of cancers as they form the functional part of all metabolic pathways and represent specific interactions with the tumor microenvironment. By studying the interrelationship between proteins expressed in healthy and diseased states, proteomics provides insight into a pathophysiological basis for target identification and molecular information to study the mechanistic basis for drug action and toxicity. Thus, there is a need for improved proteomic screening methods that would allow for earlier diagnosis of lung cancer and systematic monitoring of physiological responses of this disease.
Technologies involved in proteomics
Proteomics has been used to define tumor subsets in resected lung specimens and to distinguish primary adenocarcinomas from primary squamous cell carcinomas with 98% accuracy [20] . It has also been applied to early detection and treatment of cancers of the ovary, pancreas, prostate, oesophagus, breast, liver and rectum [21] [22] [23] [24] .
A typical proteomic analysis consists of 1) sample preparation (including depletion of highly abundant proteins and enrichment of specific types of proteins), 2) optimal separation of protein species (using 1D/2D SDS-PAGE), 3) imaging, 4) identification of protein species and their charge variants (using mass spectrometry), 5) quantification, 6) data assessment using protein databases and 7) clinical validation (using ELISA/Western blot assays) (Figure 1) . Depending on the complexity of the samples to be analysed, there are several variations in each one of the above steps, the details of which have been reviewed elsewhere [25] [26] [27] [28] .
Several excellent reviews on various aspects of proteomic techniques are available [29] [30] [31] [32] [33] and will therefore be discussed here only briefly. With advancement in mass spectrometry (MS), bioinformatics, and analytical methods, proteomic approaches greatly promote serum protein analysis and biomarker discovery ( Figure 2) . Gel based applications including the 2D-PAGE and MALDI-TOF are the main technologies used in serum cancer research for identifying the proteins, quantifying changes in protein expression and discovering novel biomarkers for diagnosis and therapy [34] . Using a non-targeted 2D electrophoresis, Bouwman et al. [35] were able to investigate how fasting for 36 h affects the proteome of platelets, peripheral blood mononuclear cells (PBMC), plasma, urine and saliva collected from healthy volunteers. Okano et al. [36] discovered lung cancer markers that appear in response to treatment with gefitinib. Combining 2D/ LC-MS approaches, our laboratory has studied a large number of differentially expressed proteins in lungcancer-induced rat sera vis-à-vis control [37] . A modified version of 2DE by fluorescent tagging of proteins (DIGE) offers relatively increased throughput, ease of use, reproducibility and accurate quantitation of differential protein expression on a single gel [38] . In a recent study, proteomic analysis of human saliva from lung cancer patients revealed 16 candidate biomarkers [39] .
Attempts are being made to develop more efficient and reproducible gel-free separation methods for quantitatively comparing protein levels among biological proteomes. One such method uses isotope coded affinity tags (ICATs), involving chemical labeling of isolated proteins and peptides by isobaric tags that facilitates comparison of the proteomes of two samples simultaneously [40] . While ICATs involve chemical modification of proteins to tag them before analysis by mass spectrometry, stable isotope labeling with amino acids in cell culture (SILAC) is a simple approach for in vivo incorporation of a label (specific amino acids) into proteins that avoids chemical manipulations. SILAC-based methods have been broadly applied in many areas of cell biology and proteomics. Using this technique, several potential protein biomarkers have been identified from the oesophageal squamous cell carcinoma secretome [41] .
Isobaric tags for relative and absolute quantification (iTRAQ) provide another gel-free technique that allows relative and absolute quantification of proteins from either cell lines or clinical samples in a single experiment [42] . It involves labeling of each peptide pool with an iTRAQ reagent (4-plex, 8-plex); they are then pooled and usually fractionated by nano-LC and analysed by MS/MS. Using iTRAQ technology, Hu et al. [43] studied multiple drug reaction mechanisms involved in gastric cancer and established the value of this technology in identifying differentially expressed proteins in cancer.
Another approach to analyse proteomes without gels is MudPIT. This method involves tryptic digestion of a protein mixture, and the resultant peptides are separated and identified by strong cation exchange (SCX) and reversed phase (RP) liquid chromatography coupled with mass spectrometry. MudPIT-based proteomics was applied to expressed prostatic secretions obtained from nine men with prostate cancer and resulted in the identification of 916 unique proteins [44] .
Protein microarrays using multiple capture antibodies have also been used to detect and identify potential biomarkers for breast cancer [45] .
Mass spectrometry is considered the primary tool for protein identification for both gel-based and gel-free techniques. Characterization of proteins by MS involves (a) protein ionization and generation of gas-phase ions, (b) separation of ions according to their mass to charge ratio and (c) detection of ions. In ICAT and MudPIT, samples are directly analysed by MS (liquid chromatography; LCMS and strong cation exchange SCX-LC; reversed phase high performance liquid chromatography RP-HPLC respectively) while in 2DE and 2D-DIGE the protein spots are first excised from the gel and then digested into peptides, followed by separation by LCMS or directly analysed by MALDI/ESI-TOF. Matrix assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI) are the two main ionization sources and time of flight (TOF), ion trap, quadrapole and fourier transform ion cyclotron (FTIC) are four different mass analyzers that are currently used for protein identification and characterization. As many known cancer biomarkers are glycoproteins, such as PSA, CA15-3, CA-125 and CEA, Zheng et al. [46] identified 49 candidate serum biomarkers with significant differences between the control and lung cancer cases, using glycoprotein capture and LC-MS/MS.
Surface enhanced laser desorption and ionization (SELDI)-TOF is a variant of MALDI-TOF/MS in which the protein mixture, spotted on a surface, is modified with a chemical functionality and is allowed to crystallize with the matrix. The high-throughput nature and simplicity of its experimental procedures make SELDI-TOF MS a promising technology for future secretome analysis and biomarker discovery [47, 48] .
Unlike traditional mass spectrometry, which detects all proteins in a biological sample in an unfocused fashion, selected reaction monitoring/multiple reaction monitoring (SRM/MRM) is a highly sensitive and selective method for the targeted quantification of an analyte. The modified mass spectrometry-based quantification technologies have recently shown that serum amyloid A (SAA2) can be a good biomarker for the detection of lung cancers [49] .
One of the upcoming and promising technologies for finding early stage lung cancer involves the use of synthetic molecules that identify and probe onto the proteins that are released into the blood. A technology has been developed (Somalogic, Colorado) where the sets of molecules associated with specific diseases are assembled onto a chip, which aids in easy screening of patients for several diseases simultaneously. However, there are inherent limitations to each technique ( Table 2) . No single method is always suitable for biomarker discovery; a combination of these methods is often chosen depending on the type of material to be analyzed, the genre of disease and previous knowledge of putative markers.
Biomarkers
Biomarkers may be structural molecules, secretory products, proteins and enzymes, or non-specific markers of cell turnover that can be used to distinguish normal from abnormal states [50, 51] . Cancer biomarkers can play an important role in early diagnosis and prognosis.
Based on the findings of the past several decades, cancer biomarkers can be classified as described in Table 3 . Diagnostic biomarkers may be present at any stage during cancer development [52] . These facilitate in the diagnosis and histopathological classification of tumors. Based on accurate and early diagnosis of a disease, suitable treatment choices can be made. The US Food and Drug Administration (FDA) has approved bladder tumor antigen (BTA) and nuclear matrix protein-22 (NMP-22) [53] as diagnostic markers for bladder cancers based on urine analysis. De Petris et al. [54] confirmed CYFRA21-1 as a diagnostic marker for lung cancer.
Prognostic biomarkers, on the other hand, provide information about stages, molecular characteristics and malignant potential of tumors that facilitate the course of therapy. Examples of clinically useful prognostic markers include hormone receptors, proliferation markers, proteases, markers of angiogenesis, growth factor receptors (Her-2/neu) and p53. An increase in annexin A3 (ANXA3), belonging to the family of calcium and phospholipid-binding proteins, has been observed as a new prognostic biomarker for lung cancer [55] .
Predictive biomarkers, also referred as response markers, help in predicting the treatment response or choosing between different treatment modalities available to cure a particular disease. For example: drugs such as erlotinib or gefitinib work only in lung cancer patients with specific mutations in the epidermal growth factor receptor (EGFR) gene [56] . Pemetrexed has been found to be an effective treatment in patients with anaplastic lymphoma kinase-positive NSCLC [57] .
An ideal biomarker should a) be highly sensitive: its concentration should increase in the presence of the disease; b) be highly specific: it should not express in the absence of the disease; c) change in accordance with clinical evolution, reflecting the current status of the disease; d) indicate the presence of relapse before symptoms reappear at the clinical level; e) be reproducible; and f) be relatively easy and inexpensive to measure in the sample.
Proteomics has helped in discovery of proteinbased biomarkers; however, the development of such biomarkers needs a systematic approach and critical evaluation before it transitions from laboratory to clinic (Figure 3) [58] . A specificity of 100% is desirable in clinical terms [59] , but may not be always practical as it may become less sensitive. Several researchers therefore use a specificity of 95% as the cut-off point [60] . The connection between sensitivity and specificity for a particular disease under prediction assigns suitable cut-off points, which give rise to a receiver operatingcharacteristic (ROC) curve. A clinically useful biomarker would be the one with the largest area under the ROC curve. Taking 100% specificity as a reference point, such ROC curves help to calculate higher sensitivity for a biomarker, thus reducing the burden of false positive cases by 5%.
Serum Based Protein Biomarkers
Blood is the treasure trove of a large number of previously unstudied protein markers and expression analysis of such proteins can help in indicating the current physiological condition of various tissues including tumors, thereby aiding in tumor signature detection [61] . For lung cancer biomarker discovery, tissues, sputum and body fluid can be of use. Amongst body fluids, blood is most commonly used as it can be easily collected with minimal invasiveness and repetitive measurements can be carried out over the time. Tumor progression as well as host responses may lead to modification of circulating proteins or peptides, making blood proteome analysis appealing for the discovery of potential biomarkers that can be helpful in early diagnosis of cancer, monitoring of disease status, development of targeted therapies, evaluation of response to therapy, and survival. However, this has its own limitations, partly due to genetic and environmental differences among patients as well as non-standardized methods of sample preparation and handling [62] . Most of the regulatory proteins involved in cancer progression are present at very low concentrations (ng mL -1 or pg mL -1 ) and may be masked by the presence of higher abundant proteins, interfering with the identification and quantification of these low abundant regulatory proteins [63] . Several combinations of pre-fractionation techniques can deplete these high abundant proteins and can also remove excess salts and lipids from serum sampleSerum biomarkers can be of three types: 1. serum proteins that are differentially expressed, or cleaved or modified in cancer patients; 2. proteins that are secreted by the tumor cells into circulation; or 3. intracellular tumor proteins that are released when tumor cells die [64] . Presently only a few blood biomarkers have proven useful for diagnosis of primary cancers. These include serum PSA for prostate cancer; bladder tumor antigen (BTA) and nuclear matrix protein-22 for bladder cancer [65, 66] ; alpha-fetoprotein (AFP) for hepatocellular carcinoma and testicular cancers; catecholamines for neuroblastoma; immunoglobulins for multiple myeloma; [67] and human epididymis protein 4 (HE4) for ovarian cancer [68] . These are currently approved by FDA but are not sensitive enough for screening and early detection in selected populations.
Lung cancer protein biomarkers in serum: current status
Though a number of serum biomarkers have been evaluated for lung cancer detection, their relatively poor sensitivities and specificities have not proved clinically useful in screening, diagnosis and follow-up. Some of these biomarkers are described below: Carcinoembryonic antigen (CEA) is a member of the family of cell surface glycoproteins that are overproduced in essentially all human colon carcinomas and in a high proportion of carcinomas at many other sites [69] . Normal blood levels of CEA typically range from 0-5 µg L -1 , while in smokers they typically increase up to 7 µg L -1 [70] . Preoperative values of CEA, even within their normal range (0 -5 ng mL ), are related to worse prognoses [71] . Although serum CEA assays have low sensitivity and specificity for diagnosing lung cancers [72] , several studies have reported statistically significant evidence for the use of CEA as a prognostic marker in NSCLC patients, but not for SCLC patients [73] [74] [75] [76] [77] .
Cytokeratin fragments (CYFRA 21-1) are polygenic polypeptides that constitute the main component of keratin filaments-one of the groups of intermediate a promising substance (biomarker) is identified through basic research in animal models, tissue, or cell cultures. In the Development Phase, a biomarker is identified in human specimens; an assay for the biomarker is developed and/or modified; analytical sensitivity of the assay for the biomarker is tested; and the clinical sensitivity of the assay is measured to meet specific biological questions such as detecting mutations for biological events, or specific clinical questions such as detecting precancerous lesions. In the Trial Phase, a biomarker is subjected to broad questions to verify the intended use, such as whether the biomarker is applicable to biological and clinical settings in a variety of conditions. The biomarker is subjected to rigorous evaluation for precision, reproducibility, accuracy and other performance characteristics, including sensitivity and specificity in controlled study designs, such as a case-control or a large prospective trial. In the Application Phase, a biomarker is field-tested for a specific clinical use, such as screening of cancer, and for its cost and effectiveness in reducing disease burden and mortality due to the disease. An unsuccessful verification or benefit may lead to a return to the discovery phase and to cycle re-entry [58] .
filaments-which are the crucial part of the cytoskeleton. CYFRA 21-1 is a fragment of cytokeratin (CK) 19 expressed in many normal and malignant epithelial cells [78] . Early clinical studies have shown that elevated levels of serum CYFRA 21-1 were detected in patients with lung cancer [79] [80] [81] . Kosacka and Jankowska [82] concluded that in NSCLC patients with strong CK19 expression (+++) in tumor cells, there is a tendency to have lower CYFRA 21-1 levels in serum. Despite extensive research it is unclear why CYFRA 21-1 is increased only in some lung cancer patients, whereas all malignant lung tumors express CK19. Studies have shown that CYFRA 21-1 was significantly elevated in all types of lung cancer (P< 0.05) with a specificity of 100% and sensitivity of 65.7%, while it is significantly elevated in NSCLC as compared to SCLC with a sensitivity of 80% and 40% respectively. In addition, CYFRA 21-1 may not only be a sensitive tumor marker in diagnoses [83] , but a high preoperative CYFRA 21-1 level is found to be a significant independent prognostic factor in patients with stage I NSCLC [84] . It is further substantiated by the finding of Tomita et al. [75] that simultaneous use of CYFRA 21-1 and CEA levels may increase the prognostic power for lung cancer patients.
Tissue polypeptide antigen (TPA) is a circulating complex of polypeptide fragments from cytokeratins 8, 18 and 19. It consists of four subunits (A1, B1, B2, C) with molecular weights between 20-45 kDa. TPA is an indicator of induced cell proliferation, and elevated serum levels of TPA may be present in several nonmalignant diseases such as bacterial and viral infections, acute hepatitis, autoimmune disorders and also during pregnancy. It has been well established that the cytokeratins are one of the most useful prognostic tumor biomarkers that help in investigating and monitoring the course of treatment for lung cancer. Out of all these cytokeratins, TPA , plays a significant role [85, 86] . As TPA is also elevated in several other diseases, it may not be specific for lung cancer. However, it has been suggested by Mumbarkar et al. [87] that TPA and CYFRA 21-1 are useful serum markers for the diagnosis of NSCLC and their combined use may provide additional information for prognosis.
Squamous cell carcinoma related antigen (SCC-Ag) is a purified subfraction of the tumor antigen 4, with a molecular weight of 45 kDa, and was originally isolated from squamous cell carcinomas of the uterine cervix [88] . Elevated serum SCC-Ag levels have also been reported in patients with squamous cell carcinoma of the bronchus and nasopharynx and occasionally in healthy volunteers as well as in patients with tumors of other histopathological origin [89] . Kagohashi et al. [90] revealed that serum SCC levels were elevated in 52.7% of 201 patients with squamous cell lung cancer (SQLC) and in only 14.2% of 438 patients with non-squamous cell lung cancer (NSQLC). Their findings support previous conclusions that the sensitivity of SCC in the detection of NSQLC is low and that assessment of SCC in the clinical management of patients with NSQLC is not recommended [91, 92] , although some investigators have reported elevated SCC levels in patients with NSQLC [85, 93] .
Soluble interleukin 2 receptor (sIL-2R:IL2) is the first soluble cytokine receptor to be well characterized and it may serve as important biomarker of disease activity in condition related to the activation and subsequent proliferation of T cells. Marino et al. [94] reported increased levels of sIL-2R in serum samples of patients with untreated lung cancer. Ginns et al. [95] confirmed that patients with SCC or adenocarcinoma have high values of sIL-2R.
Acute phase reactant proteins (APRPs) are produced by the liver during any kind of malignancy, inflammation or tissue injury. It had been established that APRPs and cancer abscessions are linked, and recent discoveries through proteomic technologies have shown that different types of cancers have different APRP alterations [96] . Haptoglobin (Hp) is one such example of an acute phase tetrameric (α2β2) glycoprotein whose increased levels have been reported in breast cancer [97] , ovarian cancer [98] and pancreatic cancer [99] . Hp not only binds to free plasma haemoglobin and prevents iron loss and renal damage, [100] it is also involved in angiogenesis [101] and cell migration [102] . A search for biomarkers using mass spectrometry in serum samples of human lung cancer patients' identified significantly increased levels of fucosylated Hp in each subtype of lung cancer as compared to controls, thus suggesting its role as a marker to monitor lung cancer progression [103] . Proteomic analyses have confirmed significant differences in concentrations of Hp β chain in sera of lung cancer patients vis-a-vis healthy individuals and patients with other types of solid tumors and respiratory diseases [104] . The Hp β chain seems to be useful in diagnosing lung cancer, but is not reliable enough as a sensitive or specific biomarker.
Serum Amyloid A (SAA) constitutes a family of apolipoproteins involved in acute phase reactions. They help in deploying immune cells to sites of inflammation, carrying cholesterol to the liver and activating the enzymes that weaken the extracellular matrix [105] . From this family, two proteins, SAA1 and SAA2, have been found to be upregulated in various cancers [106] . A recent study by Sung et al. showed elevated levels of these two proteins in lung cancer patients' blood and tissue samples vis-à-vis healthy donors and patients diagnosed with other cancers [107] . This study suggests that SAA1 and SAA2 can be explored as specific diagnostic biomarkers in the future.
Marker Enzymes
Neuron-specific enolase (NSE) is a glycolytic enzyme produced in central and peripheral neurons [108] . However, NSE activity is increased in SCLC patients and could be a potential tool for post-therapy monitoring of the disease. NSE activity was found to be raised in 75% of SCLC patients at diagnosis; in 67% of patients with limited disease and in 86% of patients with extensive disease [109] . Usually transient elevations of NSE are seen immediately after chemotherapy followed by subsequent decline to lower or normal values [110, 111] . In a study by Mahmood et al. [112] diagnostic sensitivity of NSE was found to be 86% with 67% specificity suggesting the potential of NSE as a useful tumor marker for SCLC but only to a lesser extent for NSCLC.
Tumor M2-pyruvate is an isoform of pyruvate kinase, present as an active dimer and less active tetramer. The dimeric isoform is typical of tumor cells and its level can be measured in blood. Choosing a cut-off value at 95% of specificity, sensitivity was 78% in patients with SCLC and 81% in patients with NSCLC [113] . Levels correlate well with tumor progression and remission making it a valuable tool for disease monitoring [114] .
Hormones as Cancer Biomarkers
Gastrin releasing peptide (GRP), consisting of 27 amino acids, regulates gastrointestinal hormone release [115] . It is closely related to bombesin, an amphibian skin peptide of 14 amino acids [116] ; however, it has a very short half-life and its increased concentrations in serum are rare [117, 118] . Using a radioimmunoassay for a GRP precursor, elevated plasma concentrations of pro-GRP have been found in 72% of 71 SCLC patients [119] . In a recent study by Kim et al. [120] the diagnostic sensitivity of plasma pro-GRP was estimated to be 83.8% in distinguishing SCLC from all the other conditions and 86.5% for discriminating SCLC from nonmalignant cases. The upper normal limit of pro-GRP in the circulation is 50 pg/ml. Abnormal pro-GRP levels are found in 60-70% and in 75-90% of SCLC patients with local and extensive disease, respectively. Pro-GRP is a more sensitive biomarker than NSE for SCLC, but has not been found to have independent prognostic significance n multivariate analysis [121] .
Adrenocorticotropic hormone (ACTH) Ectopic secretion of ACTH and related molecules was initially observed in 1928 by Brown et al. [122] in a patient with Cushing's syndrome and small cell carcinoma of the lung. Ectopic ACTH production has also been described in association with many malignancies, such as ovarian tumors, thymoma, islet cell cancer of the pancreas, medullary cancer of the thyroid, and carcinoid tumors [123] . Elevated serum levels of ACTH have been reported in 25-30% of patients with SCLC [124, 125] . Conflicting results have been reported concerning a possible correlation between serum levels of the hormone and stage of disease, treatment response, and survival of patients with lung cancer [126] . The common precursor to ACTH is pro-opiomelanocortin (POMC), which is abnormally elevated in the plasma of lung cancer patients with epidermoid, adeno-and small cell type [127] .
In summary, ACTH seems to be neither a specific nor a sensitive indicator of lung malignancy nor does it appear to be reliable in monitoring the response to therapy or in predicting relapses.
Antidiuretic hormone (ADH) Hyponatremia was observed in association with cancer in 1938 by Winkler and Krankshaw [128] . Schwartz et al. [129] postulated the inappropriate secretion of ADH as the cause of persistent hyponatremia in two patients with bronchogenic carcinoma. The concentration of ADH was found to be elevated in 35% of 279 patients with SCLC [130, 131] while the frequency of clinical syndrome was quite low (approximately 10% of 596 patients in six different studies) [132] . Maurer et al. [133] also found out that plasma concentrations of ADH-neurophysin were elevated in 65% of 103 patients with SCLC. In patients with initially high values, concentrations were related with therapy, though initial normal levels were of no use in disclosing subsequent relapses.
Calcitonin (CT) is a 32 amino acid peptide (molecular weight 3.42 kDa) synthesized by thyroid C cells [134] . Normally CT is secreted in response to increased plasma calcium concentration or stimulation of certain gastrointestinal hormones. The hormone inhibits the release of calcium and phosphate from bone [135] . Significant increase in the concentration of serum calcitonin has been reported earlier in familial medullary thyroid carcinoma [136] . Marked elevations have also been reported in other maliganancies such as carcinoid tumors, renal cell carcinoma, breast cancer, hepatoma and gastrointestinal cancers [137] . Calcitonin was elevated in 59% of 425 SCLC patients [138] though elevated concentrations of CT do not seem to be correlated with stage of disease. However, the data of three studies taken together show that there was an increase in calcitonin levels in 80% of 81 patients with ED, and in 56% of 71 patients with LD [139] . Wallach et al. [138] reported a decrease in serum CT levels in SCLC patients responding to chemotherapy, and an increase in progressive diseases. Mulder et al. [140] , on the contrary, reported no such effect. In conclusion, the assay of serum calcitonin seems to be a general indicator of the course of SCLC disease, but it is sufficiently reliable for evaluating the response to treatment.
Insulin-like growth factors (IGFs), or somatomedins, are polypeptides of about 7.5 kDa, having a structural similarity to pro-insulin [141] . There are contrasting reports concerning the utility of IGF as tumor markers. Macauly et al. [142] measured serum IGF-I concentrations in 42 SCLC patients and concluded that IGF-I levels do not correlate with tumor bulk or with the therapeutic responsiveness of SCLC. Reeve et al. [143] observed that IGFs were highly upregulated in the sera of SCLC as well as NSCLC patients and the levels of these proteins in blood correlate with course of treatment in such patients. Further studies are needed for better evaluation of these substances.
The sensitivity of CEA, CYFRA21-1, TPA, SCCAg, DKK1, NSE, ProGRP in the sera of lung cancer patients were 47.50%, 57.00%, 50.93%, 49.00%, 69.50%, 39.73%, and 51.48% while the specificity were 92.34%, 80.19%, 90.16%, 88.41%, 91.07%, 92.20%, and 94.89% [144] respectively. All these markers have proved to have relatively low sensitivity and therefore are of little clinical value for screening if used alone. Overall specificity is satisfactory for most of the biomarkers, ranging from 71 to 95%. Several investigators have tried to study the value of various combinations of biomarkers to improve overall sensitivity and specificity, especially for screening and early diagnosis as their levels usually correlate with extent of disease. At high elevated concentrations, cytokeratin 19 fragments, tissue polypeptide antigen and squamous cell carcinoma antigen in squamous cell lung cancer, carcinoembryonic antigen and cancer antigen 125 in adenocarcinoma, as well as progastrin-releasing peptide and neuron-specific enolase in small cell lung cancer are the best suggestive panel of markers available to date.
Potential of lung cancer protein biomarkers
There are some potential lung cancer biomarker molecules at different stages of development. The potencies of serum amyloid A [145, 146] , haptoglobinalpha [147] and a fragment of apolipoprotein A-1 [148] as lung cancer biomarkers are mentioned in some studies but need further clinical validation. Plasma kallikrein B1 (KLKB1) fragments have potential to be a biomarker for diagnosis of lung adenocarcinoma [149] . KLKB1 has homology with proteins of the serine proteasetrypsin family and is related to surface-dependent procoagulation, fibrinolysis, kinin generation, and inflammation. It also has homology with KLK3, which produces prostate specific antigen (PSA). A fragment of KLKB1 (of around 18 kDa weight), possibly containing the H4 domain of it, was elevated in lung adenocarcinoma. The finding with KLKB1 fragments supports the idea of serum peptidomes as biomarkers with great potential in lung cancer diagnosis [150, 151] . PTX3 protein or TNF inducible gene 14 encoded by PTX3 gene in humans is secreted by different cell types such as endothelial cells, mononuclear phagocytes, dendritic cells and fibroblasts upon stimulation with primary inflammatory cytokines and toll like receptor engagement. Planque et al. [152] found that serum levels of PTX3 were much higher in lung cancer patients (median = 4.91 ng/ml) compared to healthy individuals (median = 1.52 ng/ml). The diagnostic sensitivity of pentraxin at 100% specificity was found to be 68%. In a recent study, Diamandis et al. [153] confirmed Pentraxin-3 but not KLK11 or progranulin as a new serum biomarker for lung carcinoma. Pentraxin-3 was able to discriminate lung cancer patients from high-risk controls with moderate sensitivity (37% at 90% specificity and 48% at 80% specificity), which was comparable to other currently used lung cancer biomarkers. Dickkopf-1 (DKK1), a secretory protein that acts as a negative regulator of the Wnt signaling pathway, is involved in development of several cancers. DKK1 has been implicated as a novel serologic and histochemical biomarker as well as a therapeutic target for lung cancers [154] . Sheng et al. [155] have further confirmed the clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Attempts have been made to harness circulating tumor-specific autoantibodies as diagnostic biomarkers for a variety of cancers, including NSCLC. Though cancer is asymptomatic in its early stage, autoantibodies produced in response to cancer-specific antigens may be detectable due to signal amplification from the humoral immune response. To date, many autoantibody targets have been evaluated for their value in early detection as well as prognosis of lung cancer [12, 15, 18, [26] [27] [28] [29] [30] [31] . However, despite many leads, little has been done to validate these findings and to translate these promising antibodies into clinically usable tests. Farlow et al. [23] identified and validated a large number of potential tumor autoantibodies for NSCLC. Three of these autoantibodies (MTAP, fumarate hydratase and endoplasmic reticulum protein 29) represent new autoantigen targets for distinguishing NSCLC from control populations.
A study from the Fred Hutchinson Cancer Research Centre recently reported a protein signature for the Titf1/Nkx2-1 network of dysregulated proteins linked to epidermal growth factor receptors and a distinct plasma signature related to neuroendocrine development [156] . This advancement would bring the promise of a blood test closer to early diagnosis of lung cancer.
Future challenges and limitations
Large numbers of deaths associated with lung cancer have led to many studies aimed at detection and monitoring the course of the disease. As a result, several lung-specific serologic protein biomarkers have been characterized that may have potential for diagnosis and prognosis of lung cancer and may play an important role in pathophysiology of the disease, ultimately leading to better patient care. Substantial challenges still remain related to standardization, sample handling, reproducibility and marker quantitation/ ratiometric measurements and development of new bioinformatic programs that would aid in analysis of multiple parameters and samples. The use of different proteomic platforms may create some discrepancies in proteomic patterns across different research and clinical centres. The major challenge lies not only in the discovery but in the proper evaluation of candidate biomarkers. For example, before any biomarker can enter into clinical practice, it needs to be validated with patient samples. Subsequently, clinical trials would be required to show that these biomarkers can be used to detect early lung cancers, as early detection translates into improved patient survival. The efficiency of the biomarkers has to be determined by defining their specificities and sensitivities and measuring the discriminative cut-off levels through ROC curve analysis. Despite the extensive efforts made in these directions, the molecular basis of lung cancer still remains poorly understood. In order to establish the diagnostic, prognostic and therapeutic importance of biomarkers and subsequently improved understanding of the pathophysiology of lung cancer, many ethical and legal issues also need to be addressed.
Conclusions
Currently available lung cancer biomarkers are not sensitive or specific enough to be used clinically in diagnosis, stratification, prognosis, or drug responses; however, it should greatly improve in future. As a number of new potential candidates are being explored for development of useful lung cancer biomarkers, we think three aspects need to be considered. Firstly, an in-depth analysis of currently available or potential biomarkers in large number of clinical samples (including other cancer types and other diseases' conditions, especially inflammatory diseases) is required in order to validate the usefulness of these biomarkers. Secondly, more specific and low abundant biomarkers for different subtypes of lung cancers need special attention. Thirdly, a single biomarker may not be enough to predict or monitor the disease; combinations of several biomarkers need to be explored to make these really useful for clinical purposes. The biomarker (or a combination of several biomarkers) needs to be validated and get the approval of the FDA. The financial support for these studies can be provided by public and private resources. Thus, the collaboration among investigators in universities and institutes, clinicians, industrial participants and regulatory agencies is a must to bring a biomarker from laboratory to clinic.
